Description: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Home Page: www.lineagecell.com
LCTX Technical Analysis
2173 Salk Avenue
Carlsbad,
CA
92008
United States
Phone:
442 287 8990
Officers
| Name | Title |
|---|---|
| Mr. Brian M. Culley M.A., M.B.A. | CEO, Pres & Director |
| Mr. George A. Samuel III, J.D. | Gen. Counsel & Company Sec. |
| Ms. Jill Ann Howe | CFO & Principal Financial and Accounting Officer |
| Ioana C. Hone | Director of Investor Relations |
| Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D. | Sr. VP of Clinical & Medical Affairs |
| Ms. Brandi L. Roberts CPA, M.B.A. | Consultant |
| Mr. William Annett | Pres & CEO of OncoCyte Corp. |
| Dr. Rami Skaliter | Chief Exec. Officer of Cell Cure Neurosciences Ltd. |
| Ms. Alexandra Hernandez | Sr. Director of Fin. & Controller |
| Dr. Harold D. Waitz | VP of Regulatory Affairs & Quality Control |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7774 |
| Price-to-Sales TTM: | 16.0768 |
| IPO Date: | 1992-03-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |